Heron Therapeutics presentation. Heron reduced the full-year revenue guidance range from $138-156 million to $140-146 million, or $4 million at mid-point of the range.

Heron Therapeutics, Inc. (Nasdaq: HRTX) ("Heron" or the "Company"), a commercial-stage biotechnology company, today announced financial results for the three months ended March 31, 2025, and ...

Heron Therapeutics: Struggling Unsuccessfully With Its Slate Of Approved Products. Dec. 20, 2022 11:17 AM ET Heron Therapeutics, Inc. (HRTX) Stock HRTX 15 Comments 3 Likes. Out of Ignorance.

SAN DIEGO, Feb. 28, 2022 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class ...

Heron Therapeutics, Inc. (NASDAQ:HRTX) scored a major legal win on December 3, 2024, when the U.S. District Court ruled in the company’s favor in a patent dispute with Fresenius Kabi USA, LLC.

SAN DIEGO, Aug. 20, 2019 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class ...

Heron Therapeutics (HRTX) could be a solid choice for investors given its recent upgrade to a Zacks Rank #1 (Strong Buy). An upward trend in earnings estimates -- one of the most powerful forces ...

Investors eyeing a purchase of Heron Therapeutics Inc (Symbol: HRTX) stock, but cautious about paying the going market price of $2.80/share, might benefit from considering selling puts among the ...

Heron Therapeutics, a publicly traded San Diego biotechnology company that makes cancer and pain-management therapies, is laying off one-third of its workforce as part of a corporate restructuring … ...

Heron Therapeutics (HRTX) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.